Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized single-blind multicenter trial of flurbiprofen cataplasms for knee osteoarthritis
CTR20221703Phase 3Active
- Sponsor
- 九典制药
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of flurbiprofen in osteoarthritis (OA), Periarthritis humeroscapularis, tendinitis, peritendinitis, Lateral Epicondylitis (LET), sponsored by 九典制药. Started Jul 2022; status: active.
02
Drugs
flurbiprofen
03
Conditions
osteoarthritis (OA)Periarthritis humeroscapularistendinitisperitendinitisLateral Epicondylitis (LET)
Beyond the preview
Go deeper on CTR20221703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221703.